Description

The Slc30a8 Knockout MIN6 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the mouse MIN6 insulinoma cell line. It features targeted disruption of the Slc30a8 gene, which encodes the zinc transporter ZnT8, a protein critical for insulin granule zinc transport. This stable, loss-of-function cellular model is designed for studying the molecular mechanisms underlying zinc-dependent insulin maturation, storage, and secretion. The knockout cell line provides a consistent genetic background for reproducible experiments without the variability of primary islet cultures.

The MIN6 host cell line is an SV40 T antigen-immortalized mouse pancreatic beta cell line that retains glucose-responsive insulin secretion and key beta cell characteristics. These cells express essential glucose-sensing components, including GLUT2, glucokinase, and KATP channels, and undergo regulated insulin exocytosis in response to physiological glucose levels. Widely used in diabetes research, MIN6 cells offer a homogeneous, expandable model for investigating beta cell function, signal transduction, and metabolic regulation. The immortalized nature ensures long-term culture stability and experimental reproducibility.

SLC30A8 encodes ZnT8, a zinc transporter localized to insulin secretory granule membranes. ZnT8 facilitates zinc influx into granules, enabling insulin hexamer crystallization and stable hormone storage. Expression is regulated by key beta cell transcription factors PDX1 and MAFA, as well as by glucose and insulin signaling. Within the insulin secretion pathway, glucose uptake via GLUT2 and metabolism by glucokinase raise the ATP/ADP ratio, closing KATP channels, causing depolarization and calcium influx through voltage-gated calcium channels, which triggers granule exocytosis. ZnT8 directly interacts with insulin and proinsulin; its disruption abolishes granular zinc accumulation, impairing insulin maturation, granule morphology, and glucose-stimulated insulin secretion.

In MIN6 cells, Slc30a8 knockout generates a disease-relevant model of impaired insulin secretion and zinc dyshomeostasis. Since these cells maintain glucose-sensing machinery, ZnT8 loss specifically disrupts granule maturation without affecting upstream glucose metabolism. This recapitulates aspects of type 2 diabetes, where SLC30A8 polymorphisms associate with hyperglycemia and impaired glucose tolerance. The knockout cell line permits dissection of zinc-dependent insulin processing, beta cell function, and compensatory mechanisms under metabolic stress. It enables long-term studies of gene-nutrient interactions and therapeutic interventions.

This knockout cell line serves a variety of research applications, from diabetes pathophysiology to zinc transporter biology. Key assays include western blotting for ZnT8, glucose-stimulated insulin secretion (GSIS) assays, ELISA for insulin, and immunofluorescence for granule markers. Zinc-specific staining and RNA-seq further enable analysis of zinc distribution and transcriptomic changes. The model is also suited for drug screening targeting insulin secretion or zinc homeostasis in type 2 diabetes. For technical inquiries, please contact Ascent Research.